Dr. Mohamed Abdellah Ibrahim
My Social Links

Dr. Mohamed Abdellah Ibrahim

Associate Professor
Minia University, Egypt

Highest Degree
Ph.D. in Pharmacology from Chiba University, Chiba, Japan

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Pharmacological Research
62%
Clinical Pharmacology
90%
Immunopharmacology
75%
Life Sciences
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Geddawy, A., M. Hussian, M.Y. Kamel, R. Kamal and M.A. Ibrahim, 2017. Effects of liraglutide and vitamin E in fructose-induced metabolic syndrome in rats. Pharmacology, 99: 48-56.
    CrossRef  |  Direct Link  |  
  2. Abdel-Aziz, A.M., M.A. Ibrahim, A.A. El-Sheikh, M.Y. Kamel, N.M. Zenhom, S. Abdel-Raheim and H. Abdelhaleem, 2017. Effect of sofosbuvir plus daclatasvir in hepatitis C virus genotype-4 patients: Promising effect on liver fibrosis. J. Clin. Exp. Hepatol. 10.1016/j.jceh.2017.06.006.
    CrossRef  |  Direct Link  |  
  3. Morsy, M.A., M.A. Ibrahim and M.I. Abd-Elghany, 2016. Dimethyl dimethoxy biphenyl dicarboxylate attenuates hepatic and metabolic alterations in high fructose-fed rats. Toxicol. Ind. Health, 32: 59-67.
    CrossRef  |  Direct Link  |  
  4. Hafez, H.M., M.A. Ibrahim, S.A. Ibrahim, E.F. Amin, W. Goma and A.M. Abdelrahman, 2015. Potential protective effect of etanercept and aminoguanidine in methotrexate-induced hepatotoxicity and nephrotoxicity in rats. Eur. J. Pharmacol., 768: 1-12.
    CrossRef  |  Direct Link  |  
  5. Abdel-Gaber, S.A., M.A. Ibrahim, E.F. Amin, S.A. Ibrahim, R.K. Mohammed and A.M. Abdelrahman, 2015. Effect of selective versus non-selective cyclooxygenase inhibitors on ischemia-reperfusion-induced hepatic injury in rats. Life Sci., 134: 42-48.
    CrossRef  |  Direct Link  |  
  6. Ibrahim, M.A., S.A. Abdel-Gaber, E.F. Amin, S.A. Ibrahim, R.K. Mohammed and A.M. Abdelrahman, 2014. Molecular mechanisms contributing to the protective effect of levosimendan in liver ischemia-reperfusion injury. Eur. J. Pharmacol., 741: 64-73.
    CrossRef  |  Direct Link  |  
  7. Ibrahim, M.A., A.A. El-Sheikh, H.M. Khalaf and A.M. Abdelrahman, 2014. Protective effect of peroxisome proliferator activator receptor (PPAR)-α and-γ ligands against methotrexate-induced nephrotoxicity. Immunopharmacol. Immunotoxicol., 36: 130-137.
    CrossRef  |  Direct Link  |  
  8. Gomaa, W.M., M.A. Ibrahim and M.E. Shatat, 2014. Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients. Saudi J. Gastroenterol., 20: 59-65.
    CrossRef  |  Direct Link  |  
  9. Amin, E.F., M.A. Ibrahim, S.A. Ibrahim, R.R. Rofaeel and A.M. Abdelrahman, 2014. Mechanisms underlying the protective effect of sildenafil in metabolic syndrome in rats. Minia J. Med. Res., 25: 31-44.
  10. Ibrahim, M.A., M. Kelleni and A. Geddawy, 2013. Nonalcoholic fatty liver disease: Current and potential therapies. Life Sci., 92: 114-118.
    CrossRef  |  Direct Link  |  
  11. Ibrahim, M.A., M.A. Morsy, O.M. Ashour and M.I. Abdel-Ghany, 2012. Protective effects of chloroquine on high fructose-induced metabolic alterations and hepatic injury in rats. J. Egypt. Soc. T., 45: 55-62.
  12. Ibrahim, M.A., M.A. Morsy, H.M. Hafez, W.M. Gomaa and A.M. Abdelrahman, 2012. Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicol. Mech. Methods, 22: 424-431.
    CrossRef  |  Direct Link  |  
  13. Ibrahim, M.A., 2012. Rational use of drugs: A possible role of open access journals. Biochem. Pharmacol., Vol. 1. 10.4172/2167-0501.1000e125.
    CrossRef  |  Direct Link  |  
  14. Ibrahim, M.A., A.H. Saad and H.M. Abdelghani, 2011. Nitric oxide in acute liver injury: The controversy will continue. J. Egypt. Soc. T., 44: 77-84.
  15. Ibrahim, M.A., A. Saad, S. Abdelwahab and H. Abdelghany, 2011. Molecular mechanisms underlying the protective effect of telmisartan in non-alcoholic fatty liver disease: Role of proinflammatory enzymes. Egypt. J. Basic Clin. Pharmacol., 1: 1-8.
  16. Ibrahim, M., E. Farghaly, W. Gomaa, M. Kelleni and A.M. Abdelrahman, 2011. Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. Eur. J. Pharmacol., 659: 289-295.
    CrossRef  |  Direct Link  |  
  17. Ibrahim, M.A., W. Gomaa, Y. Ibrahim, H. El Hadad and M. Shatat et al., 2010. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. J. Gastrointestin. Liver Dis., 19: 387-392.
  18. Ibrahim, M.A., E. Farghaly, W. Gomaa, M. Kelleni and A. Abdelrahman, 2010. Ezetimibe inhibits proinflammatory mediators involved in the pathogenesis of non alcoholic fatty liver disease. Egypt. J. Med. Sci., 31: 247-269.
  19. Ibrahim, M.A., O.M. Ashour, Y.F. Ibrahim, H.I. El-Bitar, W. Gomaa and S.R. Abdel-Rahim, 2009. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol. Res., 60: 373-381.
    CrossRef  |  Direct Link  |  
  20. Ibrahim, M.A., T. Kanzaki, A.H. Saad and A.M. Mahmoud, 2008. Nitric oxide and fibronectin in cardiac tissue of diabetic hypertensive rats: Effect of captopril. El-Minia Med. Bull., 19: 328-339.
  21. Ibrahim, M.A., T. Kanzaki, S.I. Yamagata, N. Satoh and S. Ueda, 2005. Effect of diabetes on aortic nitric oxide synthesis in spontaneously hypertensive rats: Does captopril modulate this effect? Life Sci., 77: 1003-1014.
    CrossRef  |  Direct Link  |  
  22. Ibrahim, M.A., H. Asai, S. Satoh, N. Satoh and S. Ueda, 2004. Effect of zaprinast on nitric oxide levels in serum and aortic tissue. Methods Find. Exp. Clin. Pharmacol., 26: 19-24.
    CrossRef  |  Direct Link  |  
  23. Ibrahim, M.A., N. Satoh and S. Ueda, 2003. Possible impact of nitric oxide on the antihypertensive effect of captopril and zaprinast. Adv. Ther., 20: 143-148.
    CrossRef  |  Direct Link  |